Status:
COMPLETED
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Eligibility:
All Genders
40-80 years
Brief Summary
The purpose of this study is to determine whether there is a statistical association between changes in sputum serial levels of two cytokines, interleukin (IL)-17 and IL-6, during the treatment course...
Detailed Description
BACKGROUND: COPD is one of the most pressing healthcare problems facing our nation. AE-COPD is responsible for the bulk of healthcare costs, and much of the morbidity and decline in health status amo...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of COPD (following American Thoracic Society guidelines) and/or chronic bronchitis
- ER visit and/or hospitalization with AE-COPD
- Current or former smokers with more than 20 pack-years
- Willingness to participate in follow-up studies defined in the protocol
- Ability to give informed consent
- Exclusion criteria:
- Unstable cardiovascular disease
- Other systemic disease in which survival of more than 2 years is unlikely
- Mental incompetence or active psychiatric illness
- Currently taking more than 20 mg/day of Prednisone
- Participation in another experimental protocol within 6 weeks of study entry
- Asthma
- Cystic fibrosis
- Clinically significant bronchiectasis
- Lung cancer
- Other inflammatory or fibrotic lung disease
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00281242
Start Date
September 1 2005
End Date
July 1 2010
Last Update
January 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan at Ann Arbor
Ann Arbor, Michigan, United States, 48105